Harrow, Inc. $HROW Shares Purchased by Geode Capital Management LLC

Geode Capital Management LLC raised its stake in shares of Harrow, Inc. (NASDAQ:HROW) by 4.7% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 810,803 shares of the company’s stock after acquiring an additional 36,724 shares during the period. Geode Capital Management LLC owned approximately 2.21% of Harrow worth $24,765,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of HROW. Braidwell LP increased its holdings in shares of Harrow by 5.5% in the first quarter. Braidwell LP now owns 956,839 shares of the company’s stock valued at $25,452,000 after purchasing an additional 49,800 shares during the period. Voya Investment Management LLC grew its position in Harrow by 4,035.5% in the 1st quarter. Voya Investment Management LLC now owns 381,461 shares of the company’s stock valued at $10,147,000 after buying an additional 372,237 shares during the last quarter. Westside Investment Management Inc. increased its stake in Harrow by 4.1% in the 2nd quarter. Westside Investment Management Inc. now owns 181,056 shares of the company’s stock valued at $5,529,000 after buying an additional 7,200 shares during the period. Woodmont Investment Counsel LLC raised its position in Harrow by 2.4% during the 2nd quarter. Woodmont Investment Counsel LLC now owns 106,213 shares of the company’s stock worth $3,244,000 after buying an additional 2,520 shares during the last quarter. Finally, Nuveen LLC acquired a new stake in shares of Harrow in the 1st quarter worth $2,046,000. 72.76% of the stock is currently owned by hedge funds and other institutional investors.

Harrow Price Performance

Harrow stock opened at $41.68 on Friday. The stock has a market capitalization of $1.54 billion, a P/E ratio of -166.72 and a beta of 0.19. Harrow, Inc. has a 12-month low of $20.85 and a 12-month high of $50.72. The company has a debt-to-equity ratio of 0.78, a current ratio of 0.62 and a quick ratio of 0.58. The firm’s 50-day moving average is $40.50 and its two-hundred day moving average is $36.06.

Harrow (NASDAQ:HROW) last issued its quarterly earnings results on Monday, November 10th. The company reported $0.33 earnings per share for the quarter, beating the consensus estimate of $0.22 by $0.11. Harrow had a negative return on equity of 2.18% and a negative net margin of 4.49%.The company had revenue of $71.64 million during the quarter, compared to the consensus estimate of $73.70 million. Equities analysts predict that Harrow, Inc. will post -0.53 earnings per share for the current year.

Wall Street Analyst Weigh In

HROW has been the topic of a number of recent analyst reports. Zacks Research lowered shares of Harrow from a “strong-buy” rating to a “hold” rating in a research note on Friday, September 12th. B. Riley reaffirmed a “buy” rating and issued a $74.00 price objective (up previously from $70.00) on shares of Harrow in a report on Wednesday, October 1st. Weiss Ratings reiterated a “sell (e+)” rating on shares of Harrow in a research report on Wednesday, October 8th. Craig Hallum raised their price target on Harrow from $54.00 to $64.00 and gave the company a “buy” rating in a report on Tuesday, September 23rd. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $94.00 price target on shares of Harrow in a research note on Tuesday, November 11th. Eight equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $71.43.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.